


[도1]


Citrate of Compound 1
Olaparib
Niraparib
종양억제능
강함
IC50 (log[con.], nM)
10000
1000
100
10
1
0.1
SNU 251
OVCAR3
A2780
A2780 CR
SKOV3
NCI/ADR-RES
OVCAR5


[도2]


PEO1
PEO1-OR
Relative Intensity
8
6
4
2
0
****
FOP
TOP
PEO1-OR
%TCF activity
150
100
50
0
**
****
Control
400nM
10uM
50uM
Citrate of compound 1

[도3]


A. Experimental schematics
IVIS scan
Day 0
Day 1
IVIS scan
Day 7
IVIS scan
Day 14
IVIS scan
Day 21
IVIS scan
Day 28
Day 29
Necropsy
28 x daily 50mg/kg, Citrate of Compound 1 or vehicle (H2O), PO
* 1x 10^6 of GTFB 1016-ola resistant GFP-luc cells were injected into orthotopic intrabursal right ovary with surgery
B.
Week 4 IVIS scan
형광강도
strong
weak
Control
Citrate of Compound 1
C.
Control
Citrate of Compound 1
% Change in Flux
p=0.02
IVIS week
D.
p = 0.08
# Nodules
Control
Citrate of Compound 1
Number of tumor nodules
E.
**
Ascites Cell Volume (μl)
Control
Citrate of Compound 1
Ascites cell volume

[도4]


Anti-tumor effect of Citrate of Compound 1 in the Olaparib refractory PDX model
olaparib 획득내성 을 갖는 난소암 환자 복수
복수내 암세포
암세포 배양
CHA-OVA-13
Olaparib refractory patient
6th line Olaparib treatment → PR → PD(PFS 7 month)
sBRCA1 mutation
(a)
Olaparib
Olaparib→ Citrate of Compound 1
Citrate of Compound 1
Tumor volume(mm3)
5000
4000
3000
2000
1000
0
0
5
10
15
days
(b)